VTU offering powerful protein expression services and technology transfer at BIO-Europe 2014

VTU offering powerful protein expression services and technology transfer at BIO-Europe 2014

VTU Technology Logo

Press Release | VTU Technology GmbH

OCTOBER 26, 2014

Grambach, Austria: – Protein expression specialist VTU Technology will use November’s BIO-Europe biotechnology partnering conference in Germany to recruit new partners to exploit its versatile and world-leading Pichia pastoris protein expression platform.

Dr. Thomas Purkarthofer, VTU’s Head of Business Development, will represent VTU in Frankfurt. He will be able to provide detailed information on this next generation protein expression technology, along with other innovations and services such as high-speed expression strain development and fermentation-, downstream- and analytical process development and optimization.

Dr. Purkarthofer said he would use BIO-Europe’s Partnering ONE system to arrange a series of meetings throughout the three-day event. He is hoping to discuss ongoing project-& technology transfer opportunities, as well as outlicensing opportunities for Human Serum Albumin (HSA), Human Serum Transferrin (HST), HSA-fusion – and cell culture proteins.

“We’re looking to talk to organizations with needs and ideas for exploiting the powerful toolbox and highly versatile technology platform we have created for Pichia pastoris recombinant protein expression and production,” said Dr. Purkarthofer.

Broadest Pichia pastoris technology platform

Dr. Purkarthofer confirmed that VTU now possesses one of the most versatile and most powerful Pichia protein expression platforms in the world.

“This means we can deliver cost-effective and robust production processes within tight development timelines,” he added. To date several VTU customers have licensed and successfully scaled-up such processes for the manufacture of recombinant proteins with VTU´s Pichia system to volumes ranging from several hundred to more than 10,000 L.

About VTU Technology

VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes yielding up to 22 g/L of secreted protein for a wide range of biologics and other proteins.

VTU Technology´s powerful Pichia pastoris protein expression technology platform is based on its exclusive AOX1 promoter libraries and in-house expression platform, complemented by its optimized gene design and cloning strategies as well as high-throughput screening and cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma and life sciences, chemistry and energy.

About BIO-Europe

The 2014 Bio-Europe event is being held on November 7-9 at the Portalhaus Messe exhibition center in Frankfurt-am-Main and marks the 20th anniversary of the event.

More than 3,000 people attended the 2013 Bio-Europe event in Frankfurt, representing some 1,800 companies and organizations from 56 countries, along with 95 exhibitors. The 2013 event also featured more than 180 presentations and 18 workshops or panels.

The event is organised by EBD Group, whose sophisticated web-based partneringONE system was last year used to facilitate almost 18,000 one-to-one meetings, with some 3,600 licensing opportunities posted.

More information at: http://www.ebdgroup.com/bioeurope/index.php

Media Contact

Dr. Evelyn Trummer-Gödl, VTU Technology GmbH
Tel: +43 (0) 316 4009 4000
Email: e.trummer-goedl@vtu.com


Click on VTU offering powerful protein expression services and technology transfer at BIO Europe for other information.
Click on VTU Technology to contact the company directly.

Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com

Comments are closed.